Kymera Therapeutics (KYMR) Expected to Announce Earnings on Friday

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Friday, May 9th. Analysts expect Kymera Therapeutics to post earnings of ($0.93) per share and revenue of $11.38 million for the quarter.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. On average, analysts expect Kymera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kymera Therapeutics Stock Performance

KYMR traded down $0.30 on Friday, hitting $33.26. 500,969 shares of the company were exchanged, compared to its average volume of 556,172. The business's fifty day moving average is $29.89 and its 200 day moving average is $38.57. Kymera Therapeutics has a fifty-two week low of $19.45 and a fifty-two week high of $53.27. The firm has a market capitalization of $2.16 billion, a P/E ratio of -14.21 and a beta of 2.22.

Analysts Set New Price Targets

A number of analysts have commented on the company. HC Wainwright boosted their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Stephens reiterated an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Citigroup started coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $52.00 price objective on the stock. Finally, Leerink Partners restated an "outperform" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $56.36.

Insider Buying and Selling

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at $6,147,428.70. The trade was a 3.37 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the transaction, the insider now directly owns 80,085 shares in the company, valued at $2,438,588.25. This trade represents a 2.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,659 shares of company stock valued at $324,567. Insiders own 15.82% of the company's stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.